ReviewNeuroscience bulletin2026
The Hypothesis of Myelinodegeneration as an Initial Risk of Neuropathic Pain.
Review in Neuroscience bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelin, which wraps concentrically around axons, is composed of multiple layers of extended plasma membrane produced by myelinating cells, including oligodendrocytes in the central nervous system and Schwann cells in the peripheral nervous system. While extensively studied for roles of myelin in neuronal support and axonal insulation, their involvement in pain modulation is an emerging research area. This review examines the interplay between Schwann cells, myelinodegeneration, and pain, with a specific focus on neuropathic pain resulting from peripheral neuropathies, including diabetic peripheral neuropathy, postherpetic neuralgia, and peripheral nerve injury. Additionally, we summarize evidence implicating oligodendrocytes and myelinodegeneration in central neuropathic pain following spinal cord injury, multiple sclerosis, and stroke. In addition, we discuss potential mechanisms underlying these processes. Finally, we highlight future research directions and underscore the critical role of understanding myelin biology in developing effective treatments for chronic pain, suggesting that targeting myelination processes could offer new therapeutic strategies for chronic pain management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.